To validate these in vitro observations, immunohistochemical staining of clinical samples from tamoxifen‐resistant recurrent/metastatic patients revealed significantly higher ARL3 expression in relapsed tumor tissues compared to matched primary lesions (Figure 2H). The gene discussed is ARL3; the disease is neoplasm.